SCHEMBL6419692

SCHEMBL6419692

NN=C(c1ccccc1C(=O)O)c1nc2nonc2nc1Nc1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHODH Q02127 5/20 0.42
PIM1 P11309 2/20 0.36
FABP4 P15090 1/20 0.36
ALDH1A1 P00352 2/20 0.35
MAPT P10636 5/20 0.35
GFER P55789 1/20 0.35
NGLY1 Q96IV0 1/20 0.35
MEN1 O00255 2/20 0.34
GAA P10253 2/20 0.34
KMT2A Q03164 2/20 0.34
SMN1; SMN2 Q16637 4/20 0.34
MAPK8 P45983 3/20 0.34
TP53 P04637 3/20 0.34
AURKA O14965 2/20 0.34
CDC7 O00311 1/20 0.34
ALK Q9UM73 1/20 0.34
CDKN1A P38936 1/20 0.34
RECQL P46063 1/20 0.34
RAB9A P51151 1/20 0.34
POLB P06746 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6419681 1.00 DHODH (0.42) DHODHPIM1FABP4ALDH1A1MAPT
SCHEMBL6432628 0.87 TP53 (0.35) DHODHPIM1ALDH1A1MAPTMEN1
SCHEMBL6432637 0.87 TP53 (0.35) DHODHPIM1ALDH1A1MAPTMEN1
SCHEMBL6413560 0.86 GSK3B (0.40) MAPTMEN1KMT2ASMN1; SMN2TP53
SCHEMBL6413574 0.86 GSK3B (0.40) MAPTMEN1KMT2ASMN1; SMN2TP53
SCHEMBL6413677 0.83 KDM5B (0.42) ALDH1A1MAPTMEN1GAAKMT2A
SCHEMBL6413651 0.83 KDM5B (0.42) ALDH1A1MAPTMEN1GAAKMT2A
SCHEMBL6415968 0.83 RHOA (0.47) MAPTMEN1KMT2ARAB9ARHOA
SCHEMBL6415954 0.83 RHOA (0.47) MAPTMEN1KMT2ARAB9ARHOA
SCHEMBL6414910 0.81 CYP3A4 (0.38) PIM1ALDH1A1MAPTGFERMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds 4SC AG (DE) 2005-06-30 US disclosed
WO-2005044270-A1 OXADIAZOLOPYRAZINE DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS 4SC AG (DE) 2005-05-19 WO disclosed
EP-1529531-A1 Oxadiazolopyrazine derivatives as pharmaceutically active compounds 4SC AG (DE) 2005-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds NR5A2, NR1H2, NR2C2 DHODH 1369/4885PIM1 4383/4885FABP4 2715/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.